Business Context and Reporting Period
This Form 8-K is a current report filed by Ovid Therapeutics Inc. on May 1, 2025. The filing addresses Item 5.08 regarding Shareholder Director Nominations and the scheduling of the 2025 Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is procedural and does not contain financial performance data.
Material Changes
The primary material change reported is the rescheduling of the Company's 2025 Annual Meeting of Stockholders. The Board of Directors established July 9, 2025, as the meeting date. This represents a delay of more than 30 days from the anniversary date of the 2024 Annual Meeting, necessitating this disclosure.
Guidance, Outlook, and Management Commentary
- Meeting Details: The time and location of the 2025 Annual Meeting will be disclosed in the definitive proxy statement to be filed with the SEC.
- Record Date: The record date for determining stockholders entitled to notice and to vote is set for the close of business on May 19, 2025.
- Submission Deadlines: Stockholders intending to submit proposals under Rule 14a-8 or director nominations under the Bylaws must deliver written notice to the Company Secretary no later than May 12, 2025.
- Universal Proxy Rules: Stockholders soliciting proxies for director nominees other than the Company's nominees must provide notice under Rule 14a-19 by May 12, 2025.
Important Facts for Investors to Verify
- Verify the definitive proxy statement for the specific time and location of the July 9, 2025, Annual Meeting.
- Confirm the May 12, 2025, deadline for submitting shareholder proposals and director nominations to ensure compliance with Rule 14a-8 and the Company's Bylaws.
- Note the May 19, 2025, record date for voting eligibility.